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Cancer risk among patients with multiple sclerosis: A 
cohort study in Isfahan, Iran 
 
 
Abstract 
Background: Multiple sclerosis (MS), a central nervous system (CNS) autoimmune 
disorder, affects 2.3 million people around the world. Cancer kills around 7.5 million 
people annually. Both diseases have similar risks and intertwining molecular causes. Most 
studies focusing on MS and cancer have found an insignificant difference or reduction in 
the amount of cancer found in the MS community. 
Methods: We performed a cohort study using data from Isfahan Multiple Sclerosis Society 
(IMSS) and Isfahan cancer society and followed-up for 8 years on average (2006-2014). 
All of the 1718 MS patients were diagnosed according to McDonald’s criteria, then 
standardized incidence ratio and the numbers of expected cancer case were calculated. 
Results: While patients had an insignificant change in cancer prevalence, men had fewer 
cancer cases and women showed an increased prevalence of cancer. Certain types of 
cancer proved statistically significant. Breast cancer, nervous system cancers, and 
lymphoma were elevated in the cohort. 
Conclusion: Our results support the hypothesis that MS significantly affects certain 
cancers in a protective or associative manner. All cancer rates, except breast cancer, 
cancers located in the nervous system, and lymphomas were reduced in cohort, suggesting 
that unregulated immune function may provide protective effects to MS patients against 
cancer. 
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Multiple sclerosis (MS) is a debilitating autoimmune disease of the central nervous 
system (CNS) that causes demyelination of nerve fibers in the brain and spinal cord. While 
patients experience different levels of symptoms and patterns of affliction, the disease 
often results in increasingly severe levels of disability. It is still unknown what causes MS, 
though certain risk factors such as genetic predisposition, lifestyle, environment, and 
previous infection have been identified (1). While so much remains unknown about the 
root causes of MS, even more is unknown about how MS interacts with other clinical 
presentations of the disease. As the global medical community seeks a deeper 
understanding of this debilitating disease, there has been a rising interest to discover if MS 
has any definitive interactions with other diseases. Cancer has many of the same risk 
factors as MS (2). Similarly, as in MS, it is still not understood how so many risk factors 
integrate to cause cancer pathogenesis. Determining if cancer occurs at a higher, lower, or 
average rate in MS patients compared to the general population could suggest further 
directions for both MS and cancer research. There have been many epidemiological studies 
indicating that MS may have a protective role with regard to cancer (3-8). 
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In other words, the risk amongst MS patients for cancer 
was lower than in the general population. Fewer studies have 
found an increased risk of cancer overall for people living 
with MS. Under certain circumstances where the prevalence 
of cancer increased in the cohort, the difference could be 
attributed to an increased amount of medical surveillance in 
patients (9). However, the notion that MS is protective 
against cancer is hardly a fact. Data from the National Health 
Insurance System of Taiwan showed an increased risk of 
cancer overall and an increased risk for breast cancer alone 
(10). There have also been results that suggest cancer 
incidence occurs at the same rate in MS cohorts as it does in 
the general population (11, 12).  
To the best of our knowledge, there is no cohort study to 
investigate the risk and prevalence of cancers among patients 
with multiple sclerosis in Iran. In this study, patients with an 
average of eight years were followed-up and the prevalence 
and risk of cancers were studied. 
 
 
Methods 
Study Area: This cohort study was carried out in Isfahan, 
the third largest province of Iran (107,003 km
2
), which is 
located in the central part of Iran, between the latitudes of 30 
and 34 degrees north of the equator, and longitude of 49–55 
degrees, with altitude of 1590m. According to the last census 
which was performed by the Iranian Central Bureau of 
Statistics (ICBS) in Iran, the population of Isfahan was 
estimated around 4,815,863 (51% men and 49% women) and 
Isfahan was similar to other parts of country with respect to 
socioeconomic proportions, current demographic features, 
and lifestyles. Governmental, private and university 
hospitals, district health centers, and private physicians are 
the major places in Iran where health services are provided 
for people. 
Registration: The registration of MS patients who are 
residents of Isfahan province was established in Isfahan 
Multiple Sclerosis Society (IMSS), the only referral system 
for Isfahanian MS patients. On April 5, 2003, all 
neurological wards in Isfahan hospitals mailed letters to 
patients who are diagnosed with MS by neurologists to 
IMSS registration system. In addition, MS cases were 
diagnosed by neurologist according to McDonald’s criteria 
registered to IMSS. Since IMSS is the only supporting center 
in the province where in providing insurance and health care 
facilities such as laboratory test, rehabilitation, and clinical 
treatments and drugs for MS patients are carried out, it is 
believed that almost all of them joined IMSS to receive this 
support. However, it should be considered that maybe there 
are few MS patients who believe that they do not need these 
facilities and refuse to register to this center leading to a 
small underestimation of Isfahan MS population.  
All patients who were registered in both IMSS registration 
database and cancer registration system have the same 
national ID number which helps an easy access in the 
identification of comorbidities in the same individual. In this 
study, we also utilized the database of Isfahan cancer registry 
wherein. The system tried to cover all cancer patients 
residing in Isfahan and in this regard, their population-based 
database has been completed since 2005. While MS patients 
in both registration systems have the same code identifying 
cancer and MS patients was performed manually since IMSS 
registration is not computerized.  
Diagnostic criteria: All MS patients were diagnosed by 
their neurologists according to the McDonald’s criteria 
which is approved international diagnostic criteria for MS 
(13). According to McDonald’s criteria, patients are 
classified to three groups: Definite MS, possible MS, and no 
MS that in our study being a case of definite MS was 
considered as an including criteria. Furthermore, diagnostic 
criteria for primary progressive multiple sclerosis (PPRMS) 
was used for the diagnosis of PPMS patients (14). While the 
rate of MS patient disability was assessed according to 
Kurtzke method which is also a common method for 
measuring expanded disability status scale (EDSS) in MS 
patients (15).
 
Statistical analysis: In the present study, all statistical 
analysis was performed by SPSS software (Version 22; 
SPSS Inc., Chicago, IL, USA). Also, in this cohort study, 
standardized incidence ratio (SIR), which was calculated by 
dividing the number of observed cases of cancer by the 
numbers of expected cancer cases, represented a measure of 
the relative risk of cancer. The number of expected cases of 
cancer was calculated by multiplying a stratified rate of 
cancer incidence in Isfahan by sum of age, sex and period-
specific person years at risk in cohort. Wald’s test assuming 
a Poisson distribution of the observed cases was used for 
determining 95% confidence interval (CI) for SIR. 
 
Results 
The MS cohort included 1718 MS patients (388 men and 
1330 women) who were followed-up for average of 8 years, 
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yielding a total of 13650 person-years at risk. Three types of 
MS were observed in MS population as: relapsing–remitting 
multiple sclerosis (RRMS): 1510 (87.89%); secondary 
progressive multiple sclerosis (SPMS): 110 (6.40%); 
primary progressive multiple sclerosis (PPMS): 98 (5.70%) 
and table 1 summarizes other sociodemographic 
characteristics and clinical features of studied patients. 
Overall, 23 cancer cases have been observed during 2006-
2014 follow-up which approximately corresponds with 24 
types of expected cancers [SIR=0.95 (95% CI, 0.8-1.10)].  
 
Table 1: Sociodemographic characteristics and clinical 
features of studied patients. 
 
Characteristics Female N(%) Male N(%) 
Age at onset 
<15 
≤15 and ≤50 
≥50(0.6) 
 
70 (5.3) 
1250 (94) 
10 (0.7) 
 
17 (4.3) 
360 (92.7) 
11 (3) 
Family history of MS 
No 
Yes 
 
1174 (88.3) 
156 (11.7) 
 
331 (85.3) 
57 (14.7) 
Pattern of disease 
Relapsing-remitting 
Primary progressive 
Secondary progressive 
 
1180 (88.7) 
70 (5.3) 
80 (6) 
 
328 (84.6) 
30 (7.7) 
30 (7.7) 
Occupation 
Housewife/unemployed 
Student 
Employed 
 
939 (70.6) 
114 (8.6) 
277 (20.8) 
 
67 (17.2) 
23 (6) 
298 (76.8) 
Marital status 
Single 
Married 
Divorced/Widowed 
 
368 (27.7) 
904 (68) 
58 (4.3) 
 
124 (32) 
253 (65.2) 
11 (2.8) 
Pregnancy history 
Yes 
No 
 
953 (71.7) 
377 (28.3) 
 
- 
- 
Age(Mean±SD) (year) 31.8±9.2 33.7±9.6 
 
The mean age of MS patients with cancer is 43.2±10.4 
year. In history taking, it was revealed that only one patient 
had family history of cancer, while three others had history 
of MS in their family. Other clinical and paraclinical features 
of them are summarized in table 2. Among the 1718 MS 
patients with diagnosis of definite MS, 11 had breast cancer, 
3 lymphoma, 3 nervous system cancer, and 6 of them had 
other types of cancer (table 3). Further analysis with respect 
to the cancer sites resulted in an increased risk of breast 
cancer [SIR=1.77 (95% CI, 1.12-2.76)], lymphoma 
[SIR=1.87 (95% CI, 1.64-2.20)] and cancers which are 
located in nervous system [SIR=2.30 (95% CI, 1.01-5.05)] 
and decreased risk of other cancers [SIR=0.40 (95% CI, 
0.60-0.90] including: endocrine glands, bone, connective 
tissue, secondary and unspecified sites. While women with 
MS were at increased risk of cancers [SIR=1.09 (95% CI, 
1.05-1.14), n=21)], men who developed cancers revealed a 
statistically significant decreased risk of cancers [SIR=0.39 
(95% CI, 0.32-0.47), n=2)]. Number of observed and 
expected cancer cases and SIR with 95% CI among Isfahan 
MS patients are presented in table 3.  
 
Table 2: Clinical and paraclinical features of MS patients 
who developed cancers. 
 
Characteristic Female (%) Male (%) 
Age (year) 44.1±9.9 34±4 
Age at onset of MS (year) 31.6±8.7 25.5±3.64 
EDSS* (year) 3.05±1.93 2.5±0.5 
Presenting symptom of MS 
weakness 
cerebellar-brain stem 
sensory 
visual 
 
38.1 
14.3 
4.7 
42.9 
 
50 
0 
0 
50 
Family history of autoimmune 
disorders 
Yes 
No 
 
 
9.5 
90.5 
 
 
0 
100 
* Expanded Disability Status Scale  
 
Table 3: Observed and expected number of cancers and 
standardized incidence ratios in a cohort of MS patients 
at anatomical sites. 
Cancer site Observed Expected SIR 95%CI 
All Cancers 
Women 
Men 
23 
21 
2 
24.2 
19.1 
5.1 
0.95 
1.09 
0.39 
0.80-1.10 
1.05-1.14 
0.32-0.47 
Type of cancers  
Breast 
Lymphoma 
Nervous system 
Others 
 
11 
3 
3 
6 
 
6.2 
1.6 
1.3 
14.9 
 
1.77 
1.87 
2.30 
0.4 
 
1.12-2.76 
1.64-2.20 
1.01-5.06 
0.60-0.90 
SIR: Standard incidence ratio 
         
Caspian J Intern Med 2017; 8(3): 172-177 
Cancer risk in Multiple Sclerosis                                                                   175 
Discussion 
Taken together, we found no increased risk of cancers 
among MS patients; however, men have a statistically 
significant decreased risk of cancers, while women showed a 
slight increases risk of cancers. Furthermore, our results 
revealed that the risk of lymphoma and nervous system 
cancer are considerably higher in MS patients, suggesting 
that the pathogenesis of these cancers and MS may be 
similar. The risk of breast cancer also showed a statistically 
significant increase.  
We found no evidence of an increased risk of other 
cancers after MS diagnosis. These results are similar to 
previous studies of this sort. Comorbidity of lymphoma and 
autoimmune and chronic inflammatory disorders was 
demonstrated by a population-based study in the 
Netherlands. Although this study did not address MS 
directly, it did study the co-occurrence of MS and other 
autoimmune inflammatory diseases such as rheumatoid 
arthritis, chronic inflammatory bowel disease, and ulcers, 
amongst others (16). The underlying pathways for these 
diseases are similar to those in MS. The link between 
autoimmune disorders and lymphatic cancer may lie in an 
imbalance between anti-inflammatory cytokines and pro-
inflammatory cytokines (17). 
It is the same imbalance that may also lead to reduce 
other cancer incidence in the MS population. Many other 
studies of which some of them had larger sample sizes, 
found an overall decreased rate of cancer as well. Because 
MS involves an upregulation of the immune system, to the 
degree of destroying the myelin sheath, protection against 
most cancers could be a beneficial side-effect. The increase 
in production of anti-tumor cytokines by helper T1 (Th1) 
cells, which are the main cells implicated in autoimmune 
inflammation, would help to prevent cancers from 
proliferating (18).  
As a consequence, this may be a viable link to the role 
that MS has in cancer immunity. Our study showed a 
significant increase outside of the 95% CI for the nervous 
system cancer. While the body produces anti-tumor 
cytokines in addition to attacking its own tissues, it is 
causing obvious inflammation in the CNS. Lesions of the 
brain are one of the diagnostic signs physicians use to 
decipher MS from other neurological diseases. Inflammation 
of CNS tissue is an obvious risk factor for primary cancers 
originating in the nervous system (19). Another possibility 
for the increase seen in nervous system cancer is the 
misclassification of benign MS lesions (12). Breast cancer 
and MS have been studied not only via epidemiological 
studies, but also through familial genomic studies as well. 
The BRCA1 gene mutation, caused by a frame shift, could 
be in close proximity to an MS gene, which would explain 
why many researchers have found more breast cancer cases 
in MS patients than expected (20). Of course, this was a 
single family and a single study, so the results may not be 
very significant. It is evidence that will need to be further 
examined as gene sequencing becomes more common. 
Another issue with this explanation is that BRCA mutations 
account for a very small percentage of breast cancer cases 
(21). 
If MS patients who also have breast and ovarian cancers 
were to be tested for BRCA mutations, this could shed some 
light on the possibility of there being a significant MS gene. 
More likely than not, there are many genes that contribute to 
the likelihood of becoming afflicted with MS. The 
significant increase found for breast cancer is relatively 
common throughout these types of studies, and was 
reproduced here in our study. The other possible reason for 
these results could lie in women’s lifestyle choices, such as 
how long women wait to have children or if they have 
children at all. Another such study that found a statistically 
significant increase in breast cancer in their MS cohort was 
unable to account for the change with child-bearing related 
explanations (7).
 
One common treatment for MS is immunosuppressive 
(IS) therapy. A study looking at IS treatments and cancer 
found that the patients who were treated with IS had three 
times greater risk of developing cancer than an MS patient 
who never received IS (22). This study found a particular 
trend towards breast cancer, cancer in the urinary tract, 
digestive tract, and skin. While the overall risk of cancer was 
reduced for the portion of the cohort without any history of 
IS treatment, including a reduced risk for breast cancer in 
women, the story was different in the treatment positive 
portion of the cohort. The chances of getting these cancer 
types increased between the two groups, but did not exceed 
significance with regard to the general population.  
There is a possibility that any increase in cancer 
prevalence in an MS cohort is due to increased surveillance 
by the patient. Breast cancer in particular is a special case 
where patient concern may lead to overdiagnosis. Women 
who experienced breast cancer in situ may have never been 
diagnosed if yearly screening tools were not used such as 
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mammography and breast exam (23). The average MS 
patient will spend more time visiting doctors than an 
unaffected individual, which means there is a tendency 
towards over-vigilance. This attention to health may explain 
the discrepancies between the general population and MS 
patients when it comes to breast cancer. When MS patients 
were followed-up as well as their parents, no genetic link 
was found between patients who have cancer and MS 
comorbidity and cancer in their parents (24).  
This suggests that there is no significant genetic link 
between cancer and MS.  There was an observable increased 
risk of urinary tract cancer and brain tumors in their MS 
cohort, but an overall decreased risk of cancer, can be 
attributed to changes in behavior and immunological 
properties of the disease. 
In conclusion, our results further support the hypothesis 
that MS significantly affects only certain cancers, either in a 
protective or associative manner. While we found no 
significant change in cancer rates overall from the general 
population, we did find men to be less likely to develop 
cancer after an MS diagnosis. Women had an opposite 
response.  
The rates of cancer incidence for women were above the 
95% confidence interval calculated from general population 
rates. Further statistical analysis shows that the rates of 
breast cancer, cancers located in the nervous system, and 
lymphomas increased in the cohort of our 1718 patients. This 
could be due to many factors, including inflammatory 
consequences of autoimmune disease, patient behavior, 
genetic predispositions, and intensified health surveillance 
after diagnosis. The rates of all other cancers reduced in our 
cohort, suggesting that upregulated immune function may 
provide protective effects to MS patients against cancer. 
More research studies in this area are needed via 
epidemiology and experimental study designs that will be 
necessary to fully understand if there is a link between 
certain types of cancer and MS, and if so, what is that link. 
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